ASX listed companies have many gems underneath. There are many stocks having good business models and are potential growth companies.
Two such stocks are
Polymetals Resources Limited (ASX: POL)
Polymetals Resources Limited (ASX: POL) has delivered a comprehensive update on its 100%-owned Endeavor Project, showcasing significant progress across exploration, project development, and financing. Near-mine exploration is focused on the company’s 30 km² granted mining licenses, with regional efforts spanning 1,107 km² along 70 km of strike in the northern Cobar Superbasin. The identification of nine near-mine targets, led by the Carpark Prospect, underscores the project’s potential. Drilling at Carpark is scheduled to begin in January 2025, targeting a massive sulphide body and associated supergene mineralization.
The company has finalized a US$20 million Pre-payment Loan Facility with Ocean Partners, providing crucial funding for redevelopment. The Endeavor Project’s updated economic metrics reinforce its viability, projecting a 10-year mine life with enhanced production rates. Revenue of $1.9 billion and pre-tax cash flows of $609 million are forecast from the sale of approximately 260,000 tonnes of zinc, 90,000 tonnes of lead, and 10.6 million ounces of silver. A pre-tax IRR of 345% and an NPV (8%) of $414 million highlight its robust profitability, while the $28 million capital cost offers a rapid 14-month payback period.
Redevelopment activities, including surface and underground refurbishment, will begin in early 2025. The company is among high growth stocks as it anticipates initial cash flow in H1 2025, supported by the Endeavor Project's substantial remaining ore reserves and exploration upside. Polymetals aims to scale exploration across its 1,137 km² tenure, targeting copper, gold, silver, lead, and zinc opportunities. The partnership with Ocean Partners, built on a 20-year relationship, ensures the flexibility and funding required to restart production. This collaborative approach strengthens the project’s strategic positioning while aligning with Polymetals’ vision of sustainable growth and long-term shareholder value creation. The Endeavor Project represents a flagship asset with transformative potential, delivering compelling financial metrics and significant regional benefits. Polymetals Resources is poised to capitalize on exploration successes and operational milestones, reinforcing its path to near-term production and enhanced shareholder returns.
4DMedical Limited (ASX: 4DX)
4DMedical Limited (ASX: 4DX) has made significant strides in its expansion across both Australia and the U.S., with recent announcements showcasing the growth of its innovative respiratory imaging technology. On December 2, 2024, the company signed a commercial contract with Perth Radiological Clinic (PRC) to deploy its XV Technology®-enabled ventilation reports across 16 clinics in Perth, marking a major milestone in its Australian expansion. PRC, a leading diagnostic imaging provider in Western Australia, serves a large portion of the Perth market. The contract, which follows positive feedback from PRC’s chest radiologists after 4DMedical’s presentation at the RANZCR Annual Scientific Meeting, enables PRC to offer advanced lung diagnostics through both CT and fluoroscopy imaging. The contract, running until September 2025, highlights the growing adoption of 4DMedical’s groundbreaking technology in the healthcare sector.
4DMedical is among the best growth stocks to buy now having also expanded into the U.S. with the signing of a commercial contract with Imaging Partners of Orange County (IPOC) on November 25, 2024. This contract marks the company’s first collaboration with an independent U.S. radiology provider, following the Centers for Medicare & Medicaid Services' (CMS) approval of reimbursement for its CT LVAS™ technology. IPOC, which operates in Orange County, California, will now offer 4DMedical’s CT LVAS™ and Lung Density Analysis™ (LDAf) scans on a subscription basis. This agreement is expected to accelerate the commercialisation of 4DMedical’s lung imaging technology in the U.S., where interest has been growing, particularly after a webinar co-hosted by the California Thoracic Society that emphasized advanced imaging for diagnosing unexplained respiratory conditions.
For FY2024, 4DMedical reported a total income of $14.8 million, which includes $3.8 million in operating revenue. The company made significant investments in its U.S. market presence, including a reseller agreement with Philips, and reported a net loss of $36.0 million, primarily due to R&D, operational costs, and its acquisition of Imbio. Despite the loss, 4DMedical maintained a strong net cash position of $30.6 million and remains focused on commercialization.
Source: Company’s Report
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.